FDA approves Livsayis, a four-times-a-year shot for myasthenia gravis
Livsayis is the first siRNA drug for anti-AChR-positive generalized myasthenia gravis. In a 24-week trial, 77 percent of adults improved on daily-living scores, compared with 44 percent on placebo. It carries a meningococcal infection warning.

Read the original
The reporting lives at WebMD. Our summary is checked against it, and we link it on every story.
The FDA approved Livsayis, a shot given four times a year, for adults with anti-AChR-positive generalized myasthenia gravis, WebMD reported. It is the first siRNA drug for that form of the disease. In a 24-week trial of 123 adults, 77 percent of people on Livsayis improved meaningfully on daily-living scores, compared with 44 percent on placebo.
The approval comes with a warning about meningococcal infection, and vaccination is required. The 123 adults are the trial group. Seventy-seven percent and 44 percent are the shares who improved on those scores. This is an approval based on that trial, not a claim that every patient will see the same result.
Health & Tech in MarylandSilver Spring, MarylandMedical researchPublic healthGood news on November 19
More good news
Other stories in the same neighborhood of kindness.
Health & TechFDA approves the first drug for the neurological symptoms of Type 3 Gaucher disease
Infilbray, a daily pill that reaches the brain, improved a combined coordination and thinking score versus enzyme infusions in a 52-week trial of 43 patients. Survival was not the measure.
Verified · U.S. FDA
Health & TechThe FDA approved Lembaz, the first drug shown to help infantile-onset Niemann-Pick C patients live longer
The FDA approved Lembaz, a spinal injection every two weeks. Among 36 treated patients, median survival was 8.5 years versus 4.9 in matched controls. It carries a boxed warning for hearing loss.
Verified · U.S. Food and Drug Administration
Health & TechFDA approves Roche's oral pill giredestrant for advanced breast cancer
The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.
Verified · Reuters